Press coverage about Oxford Immunotec Global (NASDAQ:OXFD) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oxford Immunotec Global earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4734884714409 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- $25.88 Million in Sales Expected for Oxford Immunotec Global PLC (OXFD) This Quarter (americanbankingnews.com)
- -$0.36 EPS Expected for Oxford Immunotec Global PLC (OXFD) This Quarter (americanbankingnews.com)
- Oxford Immunotec to Present at the 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
- Oxford Immunotec Global Plc breached its 50 day moving average in a Bearish Manner : OXFD-US : January 1, 2018 (finance.yahoo.com)
Oxford Immunotec Global (NASDAQ:OXFD) opened at $14.06 on Monday. The stock has a market capitalization of $360.71, a PE ratio of -6.96 and a beta of -0.09. Oxford Immunotec Global has a fifty-two week low of $12.19 and a fifty-two week high of $19.51. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38.
In related news, Director Richard A. Sandberg sold 3,000 shares of Oxford Immunotec Global stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the transaction, the director now directly owns 17,778 shares of the company’s stock, valued at $237,336.30. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 8.11% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://weekherald.com/2018/01/08/oxford-immunotec-global-oxfd-receives-coverage-optimism-rating-of-0-12.html.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.